Alterity Therapeutics Limited stock is down -17.06% since 30 days ago. The next earnings date is Mar 12, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 36.36% of the previous 21 March’s closed higher than February.
Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's Disease.
Unlock Exclusive Market Insights! Receive timely updates on market developments. Sign up & stay informed!